--- title: "Cytokinetics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 28.62 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295142379.md" datetime: "2026-08-06T20:49:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295142379.md) - [en](https://longbridge.com/en/news/295142379.md) - [zh-HK](https://longbridge.com/zh-HK/news/295142379.md) generator: "portal-rs" --- # Cytokinetics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 28.62 M Revenue: As of FY2026 Q2, the actual value is USD 28.62 M, beating the estimate of USD 17.46 M. EPS: As of FY2026 Q2, the actual value is USD -1.5, beating the estimate of USD -1.6386. EBIT: As of FY2026 Q2, the actual value is USD -198.05 M. #### Cash, Cash Equivalents, and Investments As of June 30, 2026, Cytokinetics, Incorporated reported approximately $1.7 billion in cash, cash equivalents, and investments, an increase from $1.1 billion at March 31, 2026. The company generated approximately $760.1 million in net proceeds from a public offering completed in the second quarter. #### Segment Revenue - **MYQORZO Net Product Revenue**: $25.3 million for the second quarter of 2026, including $23.0 million from the U.S. and $2.3 million from Europe. For the six months ended June 30, 2026, net product revenue was $30.123 million. - **Collaboration Revenues**: $3.3 million for the second quarter of 2026, up from $2.4 million for the same period in 2025. For the six months ended June 30, 2026, collaboration revenues were $5.927 million, compared to $3.995 million for the same period in 2025. - **License and Milestone Revenues**: There were no license and milestone revenues in the second quarter of 2026, compared to $64.4 million in the second quarter of 2025. For the six months ended June 30, 2026, license and milestone revenues were $11.929 million, compared to $64.353 million for the same period in 2025. #### Operating Expenses - **Research and Development (R&D) Expenses**: $97.8 million for the second quarter of 2026, including $15.9 million of non-cash stock-based compensation expense, compared to $110.1 million for the same period in 2025, which included $13.5 million of non-cash stock-based compensation expense. For the six months ended June 30, 2026, R&D expenses were $193.332 million, compared to $208.400 million for the same period in 2025. - **Selling, General and Administrative (SG&A) Expenses**: $104.4 million for the second quarter of 2026, including $19.8 million of non-cash stock-based compensation expense, compared to $65.7 million for the same period in 2025, which included $14.0 million of non-cash stock-based compensation expense. For the six months ended June 30, 2026, SG&A expenses were $209.293 million, compared to $123.090 million for the same period in 2025. - **Cost of Goods Sold**: $2.7 million for the second quarter of 2026. For the six months ended June 30, 2026, cost of goods sold was $2.891 million. - **Collaboration Cost of Revenues**: $2.9 million for the second quarter of 2026, compared to $2.4 million for the same period in 2025. For the six months ended June 30, 2026, collaboration cost of revenues was $5.253 million, compared to $3.995 million for the same period in 2025. #### Net Loss Cytokinetics, Incorporated reported a net loss of - $198.8 million for the second quarter of 2026, compared to a net loss of - $134.4 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $404.793 million, compared to a net loss of - $295.746 million for the same period in 2025. #### Balance Sheet Highlights - **Cash and Short-Term Investments**: $1,165,686 thousand as of June 30, 2026, up from $882,221 thousand as of December 31, 2025. - **Total Assets**: $1,924,551 thousand as of June 30, 2026, compared to $1,424,537 thousand as of December 31, 2025. - **Total Liabilities**: $2,098,038 thousand as of June 30, 2026, compared to $2,084,162 thousand as of December 31, 2025. - **Total Stockholders’ Deficit**: - $173,487 thousand as of June 30, 2026, an improvement from - $659,625 thousand as of December 31, 2025. #### Operational Metrics As of June 30, 2026, Cytokinetics, Incorporated continued the U.S. commercial launch of MYQORZO, with over 700 unique healthcare providers prescribing the drug and approximately 1,500 patients dispensed MYQORZO. Internationally, MYQORZO launched in Germany in June, received marketing authorization in the United Kingdom, and gained reimbursement approval in the Netherlands effective August 1. The company also submitted New Drug Applications for aficamten in Hong Kong and Taiwan and expects to launch MYQORZO in more than five additional European markets by the first half of 2027. #### Outlook / Guidance Cytokinetics, Incorporated updated its full-year 2026 financial guidance for GAAP combined R&D and SG&A expenses to be between $860 million and $890 million, an increase from the prior guidance of $830 million to $870 million. This increase is primarily driven by commercial readiness investments to support the potential 2027 launch of MYQORZO in non-obstructive hypertrophic cardiomyopathy (nHCM). Non-cash stock-based compensation expense included in this combined expense is now projected to be $140 million to $130 million, compared to the prior guidance of $130 million to $120 million. ### Related Stocks - [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md) ## Related News & Research - [Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale](https://longbridge.com/en/news/296290252.md) - [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370](https://longbridge.com/en/news/296267986.md) - [Cytokinetics grants new-hire equity awards, stock options priced at $74.13 per share](https://longbridge.com/en/news/296264145.md) - [Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative](https://longbridge.com/en/news/296006872.md) - [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**